The conversion at $0.30/share and immediate resale registration create severe near-term selling pressure. With only $1M market cap and 158K shares outstanding, 2M new shares hitting the market will crush the stock price. Monitor for additional conversions under the $10M note facility. Traders should expect massive downward price action and avoid long exposure.
Price Chart
Executive Summary
Clearmind Medicine entered into a conversion agreement for $600,000 of convertible notes at $0.30 per share, which is significantly above the current $1M market cap implied price. This converts debt to equity at a fixed price, removing conversion price formula uncertainty but immediately diluting existing shareholders by approximately 2,000,000 new shares (versus 158,076 outstanding per the 20-F). The company also amended the floor price of future convertible notes to $0.30. The conversion occurs under an already-effective resale registration statement, meaning the shares are freely tradable immediately—creating immediate overhang.
Key Facts
- Conversion of $600,000 aggregate outstanding under two convertible notes at an agreed price of $0.30 per share.
- Conversion shares issuable: 2,000,000 common shares ($600,000 / $0.30).
- Outstanding shares as of January 19, 2026: 158,076 (pre-conversion).
- Floor price in the form of Promissory Note amended to $0.30 per share.
- Conversion shares registered for resale under an effective registration statement—no restrictive legends, immediate tradability.
- A new note will be issued for any remaining principal if the $600,000 converted is less than the full outstanding principal.
- Total potential offering under the SPAs: up to $10,000,000 in convertible promissory notes.
Financial Impact
Conversion adds ~2,000,000 new shares vs current ~158,076—a ~12.6x dilution of the current float. Immediate resale overhang of freely tradable shares.
Risk Factors
- Massive dilution: 2,000,000 new shares versus ~158,076 outstanding (12.6x increase).
- Immediate resale of unregistered shares—no lock-up or legend restrictions.
- Additional conversions possible under the $10M note facility at the same or lower price.
- Sub-$1M market cap makes the stock highly fragile to any selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-058713 |
| Document: ea0291476-6k_clearmind.htm | 0001213900-26-058713 |
| Document: 0001213900-26-058713-index-headers.html | 0001213900-26-058713 |
| Document: 0001213900-26-058713-index.html | 0001213900-26-058713 |
| Document: 0001213900-26-058713.txt | 0001213900-26-058713 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.87 (+2.17%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $5.87 (−5.78%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.87 (−14.48%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.87 (+521.82%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $5.87 (+469.90%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $5.87 (−406.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers